Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With 4 Combinations of Herceptin, Docetaxel and Pertuzumab in Patients With Locally Advanced, Inflammatory or Early Stage HER2 Positive Breast Cancer

Trial Profile

A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With 4 Combinations of Herceptin, Docetaxel and Pertuzumab in Patients With Locally Advanced, Inflammatory or Early Stage HER2 Positive Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Docetaxel
  • Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Inflammatory breast cancer
  • Focus Therapeutic Use
  • Acronyms NEOSPHERE
  • Sponsors Roche
  • Most Recent Events

    • 12 Aug 2021 Results (n=53) assessing protein expression of NRG1 in tumors and pCR rates to trastuzumab-based neoadjuvant setting as well as NRG1 gene expression in the NeoSphere trial and its relationship with pathological response, published in the Clinical Cancer Research.
    • 16 Mar 2021 According to a Roche media release, based on data from (NeoSphere, TRYPHAENA, BERENICE,CLEOPATRA ) trials, the Health Canada has granted market authorization to Perjeta (pertuzumab for injection) as a neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive)
    • 14 Dec 2019 Results of integrated retrospective analysis assessing risk of recurrence and death after neoadjuvant systemic therapy by using data from five studies (HannaH, NeoSphere, TRYPHAENA, BERENICE, KRISTINE) presented at the 42nd Annual San Antonio Breast Cancer Symposium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top